Anavex 2-73 Shows Promise in Slowing Alzheimer’s Progression
Anavex Life Sciences has announced encouraging results from a Phase 2b/3 clinical trial of their investigational oral therapy, Anavex 2-73 (blarcamesine), targeting early Alzheimer’s disease. The therapy appears to significantly decelerate cognitive and functional decline, a breakthrough in treating this debilitating condition. The study enrolled 509 participants aged 60-85 with mild cognitive impairments or mild […]